Cargando…

The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations.

Consistent chromosomal translocations involving the c-myc cellular oncogene and one of the three immunoglobin loci are typical for human Burkitt's lymphoma, induced mouse plasmacytoma (MPC) and spontaneously arising rat immunocytoma (RIC). Another plasma cell malignancy, multiple myeloma (MM),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radl, J., Punt, Y. A., van den Enden-Vieveen, M. H., Bentvelzen, P. A., Bakkus, M. H., van den Akker, T. W., Benner, R.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1990
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971422/ https://www.ncbi.nlm.nih.gov/pubmed/2310679

Ejemplares similares

The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow.
por: Croese, J. W., et al.
Publicado: (1987)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
por: Nwanze, Julum, et al.
Publicado: (2017)

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2020)

Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4‐MYC oncogenic axis in multiple myeloma
por: Agnarelli, Alessandro, et al.
Publicado: (2022)

MYC inhibitors in multiple myeloma
por: Martínez-Martín, Sandra, et al.
Publicado: (2021)

Oncogenic MYC amplifies mitotic perturbations
por: Littler, Samantha, et al.
Publicado: (2019)

Attract the best: The attraction effect as an effective strategy to enhance healthy choices
por: van den Enden, Gitta, et al.
Publicado: (2021)

Multiple myeloma and kidney transplantation: the beginning of a new era
por: Van den bosch, Ines, et al.
Publicado: (2019)

Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency
por: Barna, Maria, et al.
Publicado: (2008)

Over-expression of the c-myc proto-oncogene in colorectal carcinoma.
por: Smith, D. R., et al.
Publicado: (1993)

Coamplification of the L‐myc and N‐myc Oncogenes in a Neuroblastoma Cell Line
por: Jinbo, Takeshi, et al.
Publicado: (1989)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2015)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Myc, Oncogenic Protein Translation, and the Role of Polyamines
por: Flynn, Andrea T., et al.
Publicado: (2018)

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma
por: Wang, Lifu, et al.
Publicado: (2020)

Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis
Publicado: (1986)

Targeting the MYC Oncogene in Burkitt Lymphoma through HSP90 Inhibition
por: Poole, Candace J., et al.
Publicado: (2018)

High Intrinsic Oncogenic Potential in the Myc-Box-Deficient Hydra Myc3 Protein
por: Lechable, Marion, et al.
Publicado: (2023)

Cutaneous Anthrax, Belgian Traveler
por: Van den Enden, Erwin, et al.
Publicado: (2006)

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2018)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

B-cell precursor leukemias with MYC-rearrangement come into the limelight
por: Borkhardt, Arndt, et al.
Publicado: (2022)

Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model
por: Menu, E, et al.
Publicado: (2004)

Tumour necrosis as assessed with (18)F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
por: Kahle, Xaver U., et al.
Publicado: (2019)

Detection of the c-myc oncogene product in testicular cancer.
por: Sikora, K., et al.
Publicado: (1985)

Targeting oncogenic Myc as a strategy for cancer treatment
por: Chen, Hui, et al.
Publicado: (2018)

AMPLIFIED ALLELE OF THE HUMAN N‐myc ONCOGENE IN NEUROBLASTOMAS
por: Yamada, Masao, et al.
Publicado: (1988)

MYC Oncogene Contributions to Release of Cell Cycle Brakes
por: García-Gutiérrez, Lucía, et al.
Publicado: (2019)

Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
por: Demma, Mark J., et al.
Publicado: (2019)

Absence of the Celiac Trunk
por: Van den broecke, M., et al.
Publicado: (2019)

Absence of rearrangements in the BRCA2 gene in human cancers
por: Chin, S-F, et al.
Publicado: (2001)

Successful outcome of second allogeneic bone marrow transplantation for blastic plasmacytoid dendritic cell neoplasm with MYC locus rearrangement
por: Kato, Takeharu, et al.
Publicado: (2019)

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer
por: Vaishnavi, A., et al.
Publicado: (2013)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Digitale Signalverarbeitung: mit 262 Bildern und 87 Übungsaufgaben mit Lösungen
por: Van den Enden, A W M, et al.
Publicado: (1990)

Ras oncogene mutation in multiple myeloma
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_5uglphs9g7ps2osaim12igqae3